文献速递肿瘤 PET/CT

18F-FDG PET/CT识别局部晚期宫颈癌伴腹主动脉旁淋巴结受累患者的生存预测因素以助治疗强化

18F-FDG PET/CT Identifies Predictors of Survival in Patients with Locally Advanced Cervical Carcinoma and Paraaortic Lymph Node Involvement to Allow Intensification of Treatment.
PubMed 文献 · J Nucl Med · 2020-02-07

本回顾性多中心研究纳入2006至2016年间接受同步放化疗及扩大野放疗的局部晚期宫颈癌伴腹主动脉旁淋巴结受累患者68例,由资深核医学专家复习所有18F-FDG PET/CT并测定原发肿瘤、盆腔淋巴结及腹主动脉旁淋巴结的SUVmax、代谢肿瘤体积和总病灶糖酵解。校正年龄、分期和组织学后,盆腔淋巴结TLG、腹主动脉旁淋巴结TLG及腹主动脉旁淋巴结SUVmax与总生存显著相关(P<0.005),3年总生存率为55.5%(95%CI 40.8-68.0)。结论认为18F-FDG PET/CT能在该同质亚组中识别生存预测因素,从而可提出治疗强化。

要点

  • 68例局部晚期宫颈癌伴腹主动脉旁淋巴结受累患者纳入分析,3年总生存率55.5%(95%CI 40.8-68.0)。
  • 校正年龄、分期和组织学后,盆腔淋巴结TLG、腹主动脉旁淋巴结TLG及腹主动脉旁淋巴结SUVmax与总生存显著相关(P<0.005)。
  • 18F-FDG PET/CT可识别该同质亚组的生存预测因素,从而可提出治疗强化。

核心结论

  • 18F-FDG PET/CT能在局部晚期宫颈癌伴腹主动脉旁淋巴结受累的同质亚组中识别生存预测因素,从而可提出治疗强化。

研究设计与样本

  • 回顾性多中心研究,纳入2006至2016年间接受同步放化疗及扩大野放疗的局部晚期宫颈癌伴腹主动脉旁淋巴结受累患者68例。
  • 由资深核医学专家复习所有18F-FDG PET/CT,测定原发肿瘤、盆腔淋巴结及腹主动脉旁淋巴结的SUVmax、代谢肿瘤体积和总病灶糖酵解。
  • 采用Cox比例风险模型评估上述代谢参数与总生存的相关性。

主要发现

  • 68例患者纳入研究,3年总生存率为55.5%(95%CI 40.8-68.0)。
  • 校正年龄、分期和组织学后,盆腔淋巴结TLG、腹主动脉旁淋巴结TLG及腹主动脉旁淋巴结SUVmax与总生存显著相关(P<0.005)。

临床怎么用

  • 原文结论认为18F-FDG PET/CT可识别该亚组的生存预测因素,从而可提出治疗强化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our objective was to use 18F-FDG PET/CT to identify a high-risk subgroup requiring therapeutic intensification among patients with locally advanced cervical cancer (LACC) and paraaortic lymph node (PALN) involvement. Methods: In this retrospective multicentric study, patients with LACC and PALN involvement concurrently treated with chemoradiotherapy and extended-field radiotherapy between 2006 and 2016 were included. A senior nuclear medicine specialist in PET for gynecologic oncology reviewed all 18F-FDG PET/CT scans. Metabolic parameters including SUVmax, metabolic tumor volume, and total lesion glycolysis (TLG) were determined for the primary tumor, pelvic lymph nodes, and PALNs. Associations between these parameters and overall survival (OS) were assessed with the Cox proportional hazards model. Results: Sixty-eight patients were enrolled in the study. Three-year OS was 55.5% (95% confidence interval, 40.8-68.0). When adjusted for age, stage, and histology, pelvic lymph node TLG, PALN TLG, and PALN SUVmax were significantly associated with OS (P < 0.005). Conclusion:18F-FDG PET/CT was able to identify predictors of survival in the homogeneous subgroup of patients with LACC and PALN involvement, thus allowing therapeutic intensification to be proposed.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Leray H, Gabiache E, Courbon F, et al. 18F-FDG PET/CT Identifies Predictors of Survival in Patients with Locally Advanced Cervical Carcinoma and Paraaortic Lymph Node Involvement to Allow Intensification of Treatment. J Nucl Med. 2020. PMID: 32034109. doi:10.2967/jnumed.119.238824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。